Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816439 · ClinicalTrials.gov registry record
Imaging Cannabinoid CB1 Receptors in Alcohol Dependence
A clinical trial of Alcoholism, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 101
- Enrollment target
- 1
- Study location
NCT00816439 is a study of Alcoholism that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 101 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00816439, a study of Alcoholism, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
The cannabinoid type 1 (CB1) receptor is a protein found in the brain that is involved with the effects of marijuana; it may also play a role in the effects of alcohol dependence and withdrawal. Earlier animal studies have shown that although long-term alcohol use decreases the number of CB1 receptors in the brain, the number returns to normal after alcohol use stops. This study will use positron emission tomography (PET) and magnetic resonance imaging (MRI) scans to trace a radioactive chemical called \[11C\]MePPEP, which can locate and measure the number of CB1 receptors in the brain. Researchers will study the CB1 receptors in the brains of people with alcohol dependence, and compare the results to the CB1 receptors in the brains of people without alcohol dependence. The results of this study will be used to further research into appropriate treatment procedures for alcohol dependence. This study will include 30 men with alcohol dependence and 50 men without alcohol dependence. All of the men must be between 18 and 65 years of age. Participants in both groups must not have any medical conditions that will prevent them from undergoing PET or MRI scans. For the PET scan, participants will be injected with a small amount of \[11C\]MePPEP and will then be brought to the PET scanner. The scan will take between 3 and 4 hours, but participants will be allowed to take breaks over the course of the scan. The MRI scan will not require any injections and will take approximately 1 hour to complete. Participants without alcohol dependence will make three visits to the National Institutes of Health Clinical Center. Blood and urine samples will be taken during one visit, and participants will arrange to have an MRI scan on one visit and a PET scan on the other visit, in whichever order they prefer. Participants with alcohol dependence will undergo two PET scans: the first will be performed between 3 and 7 days after the participant last consumed alcohol, and the second will
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2008-12-29 |
| Est. Completion | 2014-08-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00816439
The ClinicalTrials.gov registry entry for NCT00816439 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (73% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 0 interventions.
NCT00816439 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00816439 about?
NCT00816439 is a clinical study titled "Imaging Cannabinoid CB1 Receptors in Alcohol Dependence". The cannabinoid type 1 (CB1) receptor is a protein found in the brain that is involved with the effects of marijuana; it may also play a role in the effects of alcohol dependence and withdrawal. Earlier animal studies have shown that although long-term alcohol use decreases the number of CB1 recepto...
What is the current status of trial NCT00816439?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2008-12-29. Estimated completion is 2014-08-28.
What conditions does trial NCT00816439 study?
This clinical trial studies the following conditions: Alcoholism.
Who is sponsoring clinical trial NCT00816439?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00816439 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Naltrexone in AUD Reward Drinkers
RECRUITING · Phase 4
-
Characterization Imaging Instruments in Alcoholics and Non-Alcoholics
RECRUITING
-
Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder
RECRUITING · NA
-
Alcohol and the Social Brain: an Alcohol-Administration Hyperscanning Study
RECRUITING
-
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)
RECRUITING · NA
-
CRP and S&A for Inpatient Veterans
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.